May 12, 2026 | Congress, Pharma, healthcare
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize the value of congress investment and deliver measurable business impact.

Medical congresses remain one of the most critical data milestones in an asset’s development, providing valuable opportunities to translate scientific innovation into clinical practice. However, many organizations still approach congresses as standalone events, with fragmented planning across therapy area teams, limited alignment to overarching disease area objectives, and limited clarity on measuring success beyond immediate metrics.
By operating as a single, integrated partner across the full data and congress lifecycle, Inizio helps clients navigate complexity, align stakeholders, and gain clearer confidence in the impact of their congress investments. Our strength lies in an unmatched vantage point – combining deep, cross-functional expertise with end-to-end visibility across the product lifecycle.
Intelligent Congress is built on this foundation. Drawing on more than 30 years of experience across therapy areas, it unites strategy, experience design, delivery, and measurement into one cohesive model. This depth and breadth enable clients to move beyond fragmented, activity-based metrics and instead focus on what truly matters – meaningful shifts in HCP understanding, engagement, and behavior.
Discover how Intelligent Congress can help you create more strategic, measurable, and impactful HCP engagement. Visit our congress page or connect with the Inizio team at booth 21157 during the ASCO® Annual Meeting 2026 to see Intelligent Congress in action.
Read full article here.
This content was provided by Inizio
Latest Content from Inizio
How will COVID-19 affect uptake of vaccinations against other diseases?
Living With Chronic Illness (Series one)
China: How pharma can maximize success in this rapidly changing emerging market
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma
Migraine market snapshot
Monitoring the impact of COVID-19 on the market access landscape
Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19
UX research
In a recent interview with PME Magazine, Dan Coffin, Director explains why the application of behavioural science will be key to better health far beyond COVID-19.Read the full article here:…
Using qualitative conjoint to assess willingness-to-pay
